Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases

Neuron

Volumn 91, Issue 1, 2016, Pages 56-66

  Bacioglu, Mehtap ^a,b,c   Maia, Luis F ^a,b,d   Preische, Oliver ^a,e   Schelle, Juliane ^a,b,c   Apel, Anja ^a,b   Kaeser, Stephan A ^a,b   Schweighauser, Manuel ^a,b,c   Eninger, Timo ^a,b,c   Lambert, Marius ^a,b   Pilotto, Andrea ^a,b   Shimshek, Derya R ^f   Neumann, Ulf ^f   Kahle, Philipp J ^a,b   Staufenbiel, Matthias ^a,b   Neumann, Manuela ^a,c   Maetzler, Walter ^a,b   Kuhle, Jens ^g   Jucker, Mathias ^a,b  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BETA SECRETASE INHIBITOR; BIOLOGICAL MARKER; NB 360; TAU PROTEIN; UNCLASSIFIED DRUG; NEUROFILAMENT PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; FEMALE; LIGHT CHAIN; MALE; MOUSE; MOUSE MODEL; NEUROFILAMENT; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; TAUOPATHY; TREATMENT RESPONSE; ANIMAL; AXON; BLOOD; BRAIN; C57BL MOUSE; CEREBROSPINAL FLUID; INTERMEDIATE FILAMENT; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOLOGY; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANIMALS; AXONS; BIOMARKERS; BRAIN; DISEASE PROGRESSION; INTERMEDIATE FILAMENTS; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURODEGENERATIVE DISEASES; NEUROFILAMENT PROTEINS;

EID: 84991281277     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2016.05.018     Document Type: Article

References (52)

1. Allen, B., Ingram, E., Takao, M., Smith, M.J., Jakes, R., Virdee, K., Yoshida, H., Holzer, M., Craxton, M., Emson, P.C., et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22 (2002), 9340–9351.
2. Bäckström, D.C., Eriksson Domellöf, M., Linder, J., Olsson, B., Öhrfelt, A., Trupp, M., Zetterberg, H., Blennow, K., Forsgren, L., Cerebrospinal Fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol. 72 (2015), 1175–1182, 10.1001/jamaneurol.2015.1449.
3. Barten, D.M., Cadelina, G.W., Hoque, N., DeCarr, L.B., Guss, V.L., Yang, L., Sankaranarayanan, S., Wes, P.D., Flynn, M.E., Meredith, J.E., et al. Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. J. Alzheimers Dis. 24:Suppl 2 (2011), 127–141, 10.3233/JAD-2011-110161.
4. Boylan, K., Yang, C., Crook, J., Overstreet, K., Heckman, M., Wang, Y., Borchelt, D., Shaw, G., Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J. Neurochem. 111 (2009), 1182–1191, 10.1111/j.1471-4159.2009.06386.x.
5. Boylan, K.B., Glass, J.D., Crook, J.E., Yang, C., Thomas, C.S., Desaro, P., Johnston, A., Overstreet, K., Kelly, C., Polak, M., Shaw, G., Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 84 (2013), 467–472, 10.1136/jnnp-2012-303768.
6. Del Tredici, K., Braak, H., Lewy pathology and neurodegeneration in premotor Parkinson's disease. Mov. Disord. 27 (2012), 597–607, 10.1002/mds.24921.
7. Eggert, K.M., Oertel, W.H., Reichmann, H., Leitlinien für Diagnoistik und Therapie in der Neurologie: Parkinson-Syndrome. Deutsche Gesellschaft für Neurologie, 2012, 1–48.
8. Eisele, Y.S., Obermüller, U., Heilbronner, G., Baumann, F., Kaeser, S.A., Wolburg, H., Walker, L.C., Staufenbiel, M., Heikenwalder, M., Jucker, M., Peripherally applied Abeta-containing inoculates induce cerebral β-amyloidosis. Science 330 (2010), 980–982, 10.1126/science.1194516.
9. Gaiottino, J., Norgren, N., Dobson, R., Topping, J., Nissim, A., Malaspina, A., Bestwick, J.P., Monsch, A.U., Regeniter, A., Lindberg, R.L., et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE 8 (2013), e75091–e75099, 10.1371/journal.pone.0075091.
10. Jack, C.R. Jr., Holtzman, D.M., Biomarker modeling of Alzheimer's disease. Neuron 80 (2013), 1347–1358, 10.1016/j.neuron.2013.12.003.
11. Kuhle, J., Plattner, K., Bestwick, J.P., Lindberg, R.L., Ramagopalan, S.V., Norgren, N., Nissim, A., Malaspina, A., Leppert, D., Giovannoni, G., Kappos, L., A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult. Scler. 19 (2013), 1597–1603, 10.1177/1352458513482374.
12. Kuhle, J., Gaiottino, J., Leppert, D., Petzold, A., Bestwick, J.P., Malaspina, A., Lu, C.-H., Dobson, R., Disanto, G., Norgren, N., et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J. Neurol. Neurosurg. Psychiatry 86 (2015), 273–279, 10.1136/jnnp-2013-307454.
13. Lépinoux-Chambaud, C., Eyer, J., Review on intermediate filaments of the nervous system and their pathological alterations. Histochem. Cell Biol. 140 (2013), 13–22, 10.1007/s00418-013-1101-1.
14. Leroy, K., Bretteville, A., Schindowski, K., Gilissen, E., Authelet, M., De Decker, R., Yilmaz, Z., Buée, L., Brion, J.-P., Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am. J. Pathol. 171 (2007), 976–992, 10.2353/ajpath.2007.070345.
15. Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Paul Murphy, M., Baker, M., Yu, X., et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25 (2000), 402–405, 10.1038/78078.
16. Liu, Q., Xie, F., Siedlak, S.L., Nunomura, A., Honda, K., Moreira, P.I., Zhua, X., Smith, M.A., Perry, G., Neurofilament proteins in neurodegenerative diseases. Cell. Mol. Life Sci. 61 (2004), 3057–3075, 10.1007/s00018-004-4268-8.
17. Lu, C.-H., Petzold, A., Kalmar, B., Dick, J., Malaspina, A., Greensmith, L., Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS. PLoS ONE, 7, 2012, 10.1371/journal.pone.0040998 e40998–e13.
18. Lu, C.-H., Macdonald-Wallis, C., Gray, E., Pearce, N., Petzold, A., Norgren, N., Giovannoni, G., Fratta, P., Sidle, K., Fish, M., et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84 (2015), 2247–2257, 10.1212/WNL.0000000000001642.
19. Luk, K.C., Kehm, V.M., Zhang, B., O'Brien, P., Trojanowski, J.Q., Lee, V.M.Y., Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J. Exp. Med. 209 (2012), 975–986, 10.1084/jem.20112457.
20. Maetzler, W., Schmid, S.P., Wurster, I., Liepelt, I., Gaenslen, A., Gasser, T., Berg, D., Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. Mov. Disord. 26 (2011), 176–181, 10.1002/mds.23358.
21. Maia, L.F., Kaeser, S.A., Reichwald, J., Hruscha, M., Martus, P., Staufenbiel, M., Jucker, M., Changes in amyloid-β and tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci. Transl. Med., 5, 2013, 194re2, 10.1126/scitranslmed.3006446.
22. Maia, L.F., Kaeser, S.A., Reichwald, J., Lambert, M., Obermüller, U., Schelle, J., Odenthal, J., Martus, P., Staufenbiel, M., Jucker, M., Increased CSF Aβ during the very early phase of cerebral Aβ deposition in mouse models. EMBO Mol. Med. 7 (2015), 895–903, 10.15252/emmm.201505026.
23. Marek, K., Jennings, D., Tamagnan, G., Seibyl, J., Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. Ann. Neurol. 64:Suppl 2 (2008), S111–S121, 10.1002/ana.21602.
24. Martin, L.J., Pan, Y., Price, A.C., Sterling, W., Copeland, N.G., Jenkins, N.A., Price, D.L., Lee, M.K., Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26 (2006), 41–50, 10.1523/JNEUROSCI.4308-05.2006.
25. Mattsson, N., Andreasson, U., Persson, S., Arai, H., Batish, S.D., Bernardini, S., Bocchio-Chiavetto, L., Blankenstein, M.A., Carrillo, M.C., Chalbot, S., et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 7 (2011), 386–395, 10.1016/j.jalz.2011.05.2243.
26. McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R. Jr., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7 (2011), 263–269, 10.1016/j.jalz.2011.03.005.
27. Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., Neuenschwander, A., Abramowski, D., Frey, P., Jaton, A.L., et al. Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 313 (2006), 1781–1784, 10.1126/science.1131864.
28. Mougenot, A.-L., Nicot, S., Bencsik, A., Morignat, E., Verchère, J., Lakhdar, L., Legastelois, S., Baron, T., Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33 (2012), 2225–2228, 10.1016/j.neurobiolaging.2011.06.022.
29. Neselius, S., Brisby, H., Theodorsson, A., Blennow, K., Zetterberg, H., Marcusson, J., CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS ONE 7 (2012), e33606–e33608, 10.1371/journal.pone.0033606.
30. Neumann, M., Kahle, P.J., Giasson, B.I., Ozmen, L., Borroni, E., Spooren, W., Müller, V., Odoy, S., Fujiwara, H., Hasegawa, M., et al. Misfolded proteinase K-resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies. J. Clin. Invest. 110 (2002), 1429–1439, 10.1172/JCI15777.
31. Neumann, U., Rueeger, H., Machauer, R., Veenstra, S.J., Lueoend, R.M., Tintelnot-Blomley, M., Laue, G., Beltz, K., Vogg, B., Schmid, P., et al. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice. Mol. Neurodegener., 10, 2015, 44, 10.1186/s13024-015-0033-8.
32. Petzold, A., Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J. Neurol. Sci. 233 (2005), 183–198, 10.1016/j.jns.2005.03.015.
33. Phinney, A.L., Horne, P., Yang, J., Janus, C., Bergeron, C., Westaway, D., Mouse models of Alzheimer's disease: the long and filamentous road. Neurol. Res. 25 (2003), 590–600, 10.1179/016164103101202020.
34. Prodoehl, J., Li, H., Planetta, P.J., Goetz, C.G., Shannon, K.M., Tangonan, R., Comella, C.L., Simuni, T., Zhou, X.J., Leurgans, S., et al. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov. Disord. 28 (2013), 1816–1822, 10.1002/mds.25491.
35. Radde, R., Bolmont, T., Kaeser, S.A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M.E., Jäggi, F., Wolburg, H., Gengler, S., et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 7 (2006), 940–946, 10.1038/sj.embor.7400784.
36. Rojas, J.C., Karydas, A., Bang, J., Tsai, R.M., Blennow, K., Liman, V., Kramer, J.H., Rosen, H., Miller, B.L., Zetterberg, H., Boxer, A.L., Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann. Clin. Transl. Neurol. 3 (2016), 216–225, 10.1002/acn3.290.
37. Sako, W., Murakami, N., Izumi, Y., Kaji, R., Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis. J. Neurol. Sci. 352 (2015), 84–87, 10.1016/j.jns.2015.03.041.
38. Scherling, C.S., Hall, T., Berisha, F., Klepac, K., Karydas, A., Coppola, G., Kramer, J.H., Rabinovici, G., Ahlijanian, M., Miller, B.L., et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann. Neurol. 75 (2014), 116–126, 10.1002/ana.24052.
39. Schweighauser, M., Bacioglu, M., Fritschi, S.K., Shimshek, D.R., Kahle, P.J., Eisele, Y.S., Jucker, M., Formaldehyde-fixed brain tissue from spontaneously ill α-synuclein transgenic mice induces fatal α-synucleinopathy in transgenic hosts. Acta Neuropathol. 129 (2015), 157–159, 10.1007/s00401-014-1360-5.
40. Sperling, R., Mormino, E., Johnson, K., The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron 84 (2014), 608–622, 10.1016/j.neuron.2014.10.038.
41. Spittaels, K., Van den Haute, C., Van Dorpe, J., Bruynseels, K., Vandezande, K., Laenen, I., Geerts, H., Mercken, M., Sciot, R., Van Lommel, A., et al. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am. J. Pathol. 155 (1999), 2153–2165, 10.1016/S0002-9440(10)65533-2.
42. Steinacker, P., Feneberg, E., Weishaupt, J., Brettschneider, J., Tumani, H., Andersen, P.M., von Arnim, C.A., Böhm, S., Kassubek, J., Kubisch, C., et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J. Neurol. Neurosurg. Psychiatry 87 (2016), 12–20, 10.1136/jnnp-2015-311387.
43. Vågberg, M., Norgren, N., Dring, A., Lindqvist, T., Birgander, R., Zetterberg, H., Svenningsson, A., Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction. PLoS ONE 10 (2015), e0135886–e0135888, 10.1371/journal.pone.0135886.
44. Valentin, M.-A., Ma, S., Zhao, A., Legay, F., Avrameas, A., Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies. J. Pharm. Biomed. Anal. 55 (2011), 869–877, 10.1016/j.jpba.2011.03.033.
45. van der Putten, H., Wiederhold, K.H., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W.P., Ruegg, M.A., et al. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20 (2000), 6021–6029.
46. Vassar, R., BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res. Ther., 6, 2014, 89, 10.1186/s13195-014-0089-7.
47. Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L.O., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. 2004. Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment., in. Presented at the Journal of internal medicine, pp. 240–246. http://dx.doi.org/10.1111/j.1365-2796.2004.01380.x.
48. Wirths, O., Weis, J., Szczygielski, J., Multhaup, G., Bayer, T.A., Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer's disease. Acta Neuropathol. 111 (2006), 312–319, 10.1007/s00401-006-0041-4.
49. Yuan, A., Rao, M.V., Veeranna, Nixon, R.A., Neurofilaments at a glance. J. Cell Sci. 125 (2012), 3257–3263, 10.1242/jcs.104729.
50. Yuan, A., Sasaki, T., Kumar, A., Peterhoff, C.M., Rao, M.V., Liem, R.K., Julien, J.-P., Nixon, R.A., Peripherin is a subunit of peripheral nerve neurofilaments: implications for differential vulnerability of CNS and peripheral nervous system axons. J. Neurosci. 32 (2012), 8501–8508, 10.1523/JNEUROSCI.1081-12.2012.
51. Yuan, A., Sershen, H., Veeranna, Basavarajappa, B.S., Kumar, A., Hashim, A., Berg, M., Lee, J.H., Sato, Y., Rao, M.V., et al. Neurofilament subunits are integral components of synapses and modulate neurotransmission and behavior in vivo. Mol. Psychiatry 20 (2015), 986–994, 10.1038/mp.2015.45.
52. Zetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J.Q., Portelius, E., Shaw, L.M., Weiner, M.W., Blennow, K., Alzheimer's Disease Neuroimaging Initiative. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 73 (2016), 60–67, 10.1001/jamaneurol.2015.3037.